

CLAIMS:

1. Use of an effective amount of a compound of Formula (Ia),



(Ia)

wherein

A is 

;

X_1 is selected from O and S;

Y_1 is O;

R_1, R_4, R_5 and R_8 are independently selected from H and halogen;

R_3 and R_6 are independently selected from H, CN, OH, CF_3, halogen, and alkyl;

R_2 is OH and R_7 is selected from halogen, CN, CF_3, CO_2H, NO_2, NHAc, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, alkylamino, alkyl-R_9, alkenyl-R_9, alkynyl-R_9, OR_{10}, NHR_{10}, $NR_{11}C(O)R_{12}$, $C(O)NR_{11}R_{12}$, and $NR_{11}SO_2R_{12}$;

each occurrence of R_9 is independently selected from OH, NH_2, O-alkyl, O-alkyl-O-alkyl, alkylamino, NHC(O)-alkyl, $N(CH_3)C(O)$-alkyl, $NHSO_2$-alkyl, $N(CH_3)SO_2$-alkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl;

R_{10} is selected from C_2-C_{12} alkyl, C(O)-alkyl, hydroxyalkyl, aminoalkyl, alkyl-O-alkyl, alkyl-O-alkyl-OH, alkyl-O-alkyl-O-alkyl, alkenyl, alkynyl, arylalkyl, heteroarylalkyl, alkyl-cycloalkyl, alkyl-heterocycloalkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, SO_3H, SO_2-alkyl, and SO_2-haloalkyl;

each occurrence of R_{11} is selected from H and alkyl; and

each occurrence of R_{12} is selected from alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, O-alkyl, aminoalkyl, arylalkyl, heteroarylalkyl, alkyl-cycloalkyl, and alkyl-heterocycloalkyl;


or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a neuromuscular disorder, muscle disorder, heart disease, pulmonary fibrosis, liver disease, inflammatory bowel disease, cancer, or cognitive impairment,

wherein

the neuromuscular disorder is Charcot-Marie-Tooth disease;

the muscle disorder is hereditary inclusion body myositis, oculopharyngeal muscular dystrophy, inclusion body myopathy with Paget's disease of bone, or frontotemporal dementia; and

the heart disease is heart failure, a myocardial infarction, coronary artery disease (CAD), congestive heart failure (CHF), angina, stroke, arrhythmia, fibrillation, peripheral artery disease (PAD), or a cardiac or arterial disorder.

2. The use of claim 1, wherein A is .

3. The use of claim 1 or 2, wherein

R_9 is selected from OH, substituted cycloalkyl and heterocycloalkyl;

R_{10} is selected from alkyl, substituted cycloalkyl, heterocycloalkyl and alkyl heterocycloalkyl; and

R_{11} is H and R_{12} is alkyl-heterocycloalkyl.

4. The use of any one of claims 1-3, wherein

R_7 is selected from haloalkyl, substituted cycloalkyl, alkynyl-R_9, OR_{10}, and $C(O)NR_{11}R_{12}$;

R_9 is selected from OH, substituted cycloalkyl and heterocycloalkyl;

R_{10} is selected from alkyl, substituted cycloalkyl, heterocycloalkyl and alkyl heterocycloalkyl; and

R_{11} is H and R_{12} is alkyl-heterocycloalkyl.


5. The use of claim 3 or 4, wherein each occurrence of substituted cycloalkyl is independently substituted with OH, halogen, or hydroxyalkyl.

6. The use of any one of claims 1-5, wherein R_1, R_3, R_4, R_5, R_6, and R_8 are each H.

7. The use of any one of claims 1-5, wherein one of R_1, R_3, R_4, R_5, R_6, and R_8 is not H; or two of R_1, R_3, R_4, R_5, R_6, and R_8 are not H.


8. The use of claim 7, wherein one of R_1, R_3, R_4, R_5, R_6, and R_8 is alkyl or halogen; or two of R_1, R_3, R_4, R_5, R_6, and R_8 are independently alkyl or halogen.




















9. The use of claim 8, wherein the compound is selected from:

















































and .

10. The use of claim 1, wherein the compound is selected from:





,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,


,



11. The use of claim 1, wherein the compound is selected from:




12. Use of an effective amount of a compound of Formula (Ic),



(Ic)

wherein

A is ;

one of *n* and *m* is 0; and the other of *n* and *m* is 1;

X_1 and Y_1 are each O;

R_1, R_2, R_3, R_6, R_7, and R_8 are independently selected from H, OH, OCH_3, OAc, NH_2, halogen, CN, CF_3, CO_2H, NO_2, NHAc, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, alkylamino, alkyl-R_9, alkenyl-R_9, alkynyl-R_9, OR_{10}, NHR_{10}, $NR_{11}C(O)R_{12}$, $C(O)NR_{11}R_{12}$, and $NR_{11}SO_2R_{12}$;

R_4 and R_5 are independently selected from H, halogen and alkyl;

each occurrence of R_9 is independently selected from OH, NH_2, O-alkyl, O-alkyl-O-alkyl, alkylamino, NHC(O)-alkyl, $N(CH_3)C(O)$-alkyl, $NHSO_2$-alkyl, $N(CH_3)SO_2$-alkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl;

R_{10} is selected from C_2-C_{12} alkyl, hydroxyalkyl, aminoalkyl, alkyl-O-alkyl, alkyl-O-alkyl-OH, alkyl-O-alkyl-O-alkyl, alkenyl, alkynyl, arylalkyl, heteroarylalkyl, alkyl-cycloalkyl, alkyl-heterocycloalkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, SO_3H, SO_2-alkyl, and SO_2-haloalkyl;

each occurrence of R_{11} is selected from H and alkyl; and

each occurrence of R_{12} is selected from alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, O-alkyl, aminoalkyl, arylalkyl, heteroarylalkyl, alkyl-cycloalkyl, and alkyl-heterocycloalkyl,

or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a neuromuscular disorder, muscle disorder, heart disease, pulmonary fibrosis, liver disease, inflammatory bowel disease, cancer, or cognitive impairment,















wherein

the neuromuscular disorder is Charcot-Marie-Tooth disease;




the muscle disorder is hereditary inclusion body myositis, oculopharyngeal muscular dystrophy, inclusion body myopathy with Paget's disease of bone, or frontotemporal dementia; and

the heart disease is heart failure, a myocardial infarction, coronary artery disease (CAD), congestive heart failure (CHF), angina, stroke, arrhythmia, fibrillation, peripheral artery disease (PAD), or a cardiac or arterial disorder.


13. The use of claim 12, wherein the compound is selected from:

14. The use of claim 12, wherein the compound is:




, or

.

15. Use of an effective amount of a compound of Formula (Id),



(Id)

wherein

A is ;

Y_2 is O;

Y_3 and Y_4 are independently selected from H, halogen and alkyl; or together with the carbon to which they are bonded combine to form a cycloalkyl or heterocycloalkyl;

R_1, R_4, R_5, and R_8 are independently selected from H and halogen;

R_2, R_3, R_6, and R_7 are independently selected from H, OH, OCH_3, OAc, NH_2, halogen, CN, CF_3, CO_2H, NO_2, NHAc, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, alkylamino, alkyl-R_9, alkenyl-R_9, alkynyl-R_9, OR_{10}, NHR_{10}, $NR_{11}C(O)R_{12}$, $C(O)NR_{11}R_{12}$, and $NR_{11}SO_2R_{12}$;

each occurrence of R_9 is independently selected from OH, NH_2, O-alkyl, O-alkyl-O-alkyl, alkylamino, NHC(O)-alkyl, $N(CH_3)C(O)$-alkyl, $NHSO_2$-alkyl, $N(CH_3)SO_2$-alkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl;

R_{10} is selected from C_2-C_{12} alkyl, hydroxyalkyl, aminoalkyl, alkyl-O-alkyl, alkyl-O-alkyl-OH, alkyl-O-alkyl-O-alkyl, alkenyl, alkynyl, arylalkyl, heteroarylalkyl, alkyl-cycloalkyl, alkyl-heterocycloalkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, SO_3H, SO_2-alkyl, and SO_2-haloalkyl;

each occurrence of R_{11} is selected from H and alkyl; and

each occurrence of R_{12} is selected from alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, O-alkyl, aminoalkyl, arylalkyl, heteroarylalkyl, alkyl-cycloalkyl, and alkyl-heterocycloalkyl;

or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a neuromuscular disorder, muscle disorder, heart disease, pulmonary fibrosis, inflammatory bowel disease, cancer, or cognitive impairment,

wherein


the neuromuscular disorder is Charcot-Marie-Tooth disease;








the muscle disorder is hereditary inclusion body myositis, oculopharyngeal muscular dystrophy, inclusion body myopathy with Paget's disease of bone, or frontotemporal dementia;

the heart disease is heart failure, a myocardial infarction, coronary artery disease (CAD), congestive heart failure (CHF), angina, stroke, arrhythmia, fibrillation, peripheral artery disease (PAD), or a cardiac or arterial disorder; and






















the pulmonary fibrosis is pulmonary fibrosis is idiopathic pulmonary fibrosis.

16. The use of claim 15, wherein the compound is selected from:









, and .


17. The use of claim 15, wherein the compound is selected from:




, and .

18. Use of an effective amount of a compound of Formula (Ie),



(Ie)

wherein

A is ;

n and *m* are both 0; or one of *n* and *m* is 0, and the other of *n* and *m* is 1;

X_1 is O;

Y_1 is selected from NH, N-CH_3, N-*t*-Bu, N-cycloalkyl, and N-heterocycloalkyl;

R_1, R_2, R_3, R_6, R_7, and R_8 are independently selected from H, OH, OCH_3, OAc, NH_2, halogen, CN, CF_3, CO_2H, NO_2, NHAc, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, alkylamino, alkyl-R_9, alkenyl-R_9, alkynyl-R_9, OR_{10}, NHR_{10}, $NR_{11}C(O)R_{12}$, $C(O)NR_{11}R_{12}$, and $NR_{11}SO_2R_{12}$;

R_4 and R_5 are independently selected from H, alkyl, and halogen;

each occurrence of R_9 is independently selected from OH, NH_2, O-alkyl, O-alkyl-O-alkyl, alkylamino, NHC(O)-alkyl, $N(CH_3)C(O)$-alkyl, $NHSO_2$-alkyl, $N(CH_3)SO_2$-alkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl;

R_{10} is selected from C_2-C_{12} alkyl, hydroxyalkyl, aminoalkyl, alkyl-O-alkyl, alkyl-O-alkyl-OH, alkyl-O-alkyl-O-alkyl, alkenyl, alkynyl, arylalkyl, heteroarylalkyl, alkyl-cycloalkyl, alkyl-heterocycloalkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, SO_3H, SO_2-alkyl, and SO_2-haloalkyl;

each occurrence of R_{11} is selected from H and alkyl; and

each occurrence of R_{12} is selected from alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, O-alkyl, aminoalkyl, arylalkyl, heteroarylalkyl, alkyl-cycloalkyl, and alkyl-heterocycloalkyl;

or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a neuromuscular disorder, muscle disorder, heart disease, inflammatory bowel disease, cancer, or cognitive impairment,


wherein





















the neuromuscular disorder is Charcot-Marie-Tooth disease;

the muscle disorder is hereditary inclusion body myositis, oculopharyngeal muscular dystrophy, inclusion body myopathy with Paget's disease of bone, or frontotemporal dementia; and





the heart disease is a myocardial infarction, coronary artery disease (CAD), congestive heart failure (CHF), angina, stroke, arrhythmia, fibrillation, peripheral artery disease (PAD), or a cardiac or arterial disorder.








19. The use of claim 18, wherein the compound is selected from:


















,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

, and

.

20. The use of claim 18, wherein the compound is selected from:



,

,

,

,







, and .

21. The use of claim 18, wherein the compound is selected from:


























, and .

22. Use of an effective amount of a compound of Formula (If),



(If)

wherein

A is selected from , , , , , , , , , , , , and ;

R_1, R_2, R_3, R_6, R_7, and R_8 are independently selected from H, OH, OCH_3, OAc, NH_2, halogen, CN, CF_3, CO_2H, NO_2, NHAc, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, alkylamino, alkyl-R_9, alkenyl-R_9, alkynyl-R_9, OR_{10}, NHR_{10}, $NR_{11}C(O)R_{12}$, $C(O)NR_{11}R_{12}$, and $NR_{11}SO_2R_{12}$,

R_4 and R_5 are independently selected from H, alkyl, and halogen;

each occurrence of R_9 is independently selected from OH, NH_2, O-alkyl, O-alkyl-O-alkyl, alkylamino, NHC(O)-alkyl, $N(CH_3)C(O)$-alkyl, $NHSO_2$-alkyl, $N(CH_3)SO_2$-alkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl;

R_{10} is selected from C_2-C_{12} alkyl, hydroxyalkyl, aminoalkyl, alkyl-O-alkyl, alkyl-O-alkyl-OH, alkyl-O-alkyl-O-alkyl, alkenyl, alkynyl, arylalkyl, heteroarylalkyl, alkyl-cycloalkyl,

alkyl-heterocycloalkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, SO_3H, SO_2-alkyl, and SO_2-haloalkyl;

each occurrence of R_{11} is selected from H and alkyl; and

each occurrence of R_{12} is selected from alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, O-alkyl, aminoalkyl, arylalkyl, heteroarylalkyl, alkyl-cycloalkyl, and alkyl-heterocycloalkyl;

or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a neuromuscular disorder, muscle disorder, heart disease, pulmonary fibrosis, liver disease, inflammatory bowel disease, cancer, or cognitive impairment,


wherein


the neuromuscular disorder is Charcot-Marie-Tooth disease;


the muscle disorder is hereditary inclusion body myositis, oculopharyngeal muscular dystrophy, inclusion body myopathy with Paget's disease of bone, or frontotemporal dementia; and

the heart disease is heart failure, a myocardial infarction, coronary artery disease (CAD), congestive heart failure (CHF), angina, stroke, arrhythmia, fibrillation, peripheral artery disease (PAD), or a cardiac or arterial disorder.


23. The use of claim 22, wherein the compound is selected from:








24. The use of claim 22, wherein the compound is selected from:





25. Use of an effective amount of a compound of Formula (Ih),



(Ih)

wherein

A is selected from  or ;

n and *m* are both 0; or one of *n* and *m* is 0 and the other of *n* and *m* is 1;

r and *s* are both 0; or one of *r* and *s* is 0 and the other of *r* and *s* is 1;

X_1 is O;

Y_1 is selected from O, NH, N-alkyl, and N-cycloalkyl;

Y_2 is O;

Y_3 and Y_4 are independently selected from H, halogen, and alkyl, or together with the carbon to which they are bonded combine to form a cycloalkyl or cycloheteroalkyl;

R_1, R_4, R_5 and R_8 are independently selected from H and halogen;

R_3 and R_6 are independently selected from H, CN, OH, CF_3, halogen, and alkyl;

one of R_2 and R_7 is selected NH_2, $NHCH_3$, and $N(CH_3)_2$ and the other of R_2 and R_7 is selected from H, halogen, OCH_3, CN, CF_3, CO_2H, NO_2, NHAc, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, alkylamino, alkyl-R_9, alkenyl-R_9, alkynyl-R_9, OR_{10}, NHR_{10}, $NR_{11}C(O)R_{12}$, $C(O)NR_{11}R_{12}$, and $NR_{11}SO_2R_{12}$;

each occurrence of R_9 is independently selected from OH, NH_2, O-alkyl, O-alkyl-O-alkyl, alkylamino, NHC(O)-alkyl, $N(CH_3)C(O)$-alkyl, $NHSO_2$-alkyl, $N(CH_3)SO_2$-alkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl;

R_{10} is selected from H, C_2-C_{12} alkyl, hydroxyalkyl, aminoalkyl, alkyl-O-alkyl, alkyl-O-alkyl-OH, alkyl-O-alkyl-O-alkyl, alkenyl, alkynyl, arylalkyl, heteroarylalkyl, alkyl-cycloalkyl, alkyl-heterocycloalkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, SO_3H, SO_2-alkyl, and SO_2-haloalkyl;

each occurrence of R_{11} is selected from H and alkyl; and

each occurrence of R_{12} is selected from alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, O-alkyl, aminoalkyl, arylalkyl, heteroarylalkyl, alkyl-cycloalkyl, and alkyl-heterocycloalkyl;

or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a neuromuscular disorder, muscle disorder, heart disease, pulmonary fibrosis, liver disease, inflammatory bowel disease, cancer, or cognitive impairment,


wherein




















the neuromuscular disorder is Charcot-Marie-Tooth disease;











the muscle disorder is hereditary inclusion body myositis, oculopharyngeal muscular dystrophy, inclusion body myopathy with Paget's disease of bone, or frontotemporal dementia; and

the heart disease is heart failure, a myocardial infarction, coronary artery disease (CAD), congestive heart failure (CHF), angina, stroke, arrhythmia, fibrillation, peripheral artery disease (PAD), or a cardiac or arterial disorder.













26. The use of claim 25, wherein the compound is selected from:















,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

















and

.






















27. The use of claim 25, wherein the compound is selected from:

















,

,

,

,

,

,

,

,

,

, and

.

28. The use of claim 25, wherein the compound is selected from:


,

,

,

,

,

,

,

, and .

or a pharmaceutically acceptable salt thereof.

29. The use of any one of claims 1-28, wherein the medicament is for treating a neuromuscular disorder.

30. The use of any one of claims 1-28, wherein the medicament is for treating a muscle disorder.

31. The use of any one of claims 1-17 or 22-28, wherein the medicament is for treating pulmonary fibrosis, wherein the pulmonary fibrosis is optinally idiopathic pulmonary fibrosis.

32. The use of any one of claims 1-14 or 22-28, wherein medicament is for treating a liver disease, wherein the liver disease is optionally non-alcoholic steatohepatitis.

33. The use of any one of claims 1-28, wherein the medicament is for treating an inflammatory bowel disease, wherein the inflammatory bowel disease is optionally ulcerative colitis or Crohn's disease.

34. The use of any one of claims 1-28, wherein the medicament is for treating cancer, wherein the cancer is optionally the cancer is bladder cancer, breast cancer, cervical cancer, colorectal cancer, esophageal cancer, head and neck cancer, kidney cancer, leukemia, liver cancer, lung cancer, lymphoma, melanoma, prostate cancer, or skin cancer.

35. The use of claim 34, wherein the cancer is responsive to immunotherapy; and the medicament enhances the anti-tumor response of the immunotherapy.

36. The use of any claim 34 or 35, wherein the medicament is for concurrent administration with cancer immunotherapy; and the medicament enhances the immune response to tumor cells in the subject; the compound promotes formation of T memory stem cells

(T_{SCM}); the medicament enhances the effectiveness of the cancer immunotherapy; and/or the medicament promotes anti-tumor function upon adoptive cell transfer.

37. The use of claim 34 or 35, wherein the medicament is for is concurrent administration with an immune checkpoint inhibitior, wherein the immune checkpoint inhibitior is optionally pembrolizumab, nivolumab, or ipilimumab.

38. The use of any one of claims 1-28, wherein the medicament is for treating heart disease.

39. The use of claim 38, wherein the medicament reduces heart failure following myocardial infarction; the medicament reduces left ventricular systolic dysfunction following myocardial infarction; the medicament increases ejection fraction; and/or the medicament increases fractional shortening.

40. The use of any one of claims 1-28, wherein the medicament is for treating cognitive impairment.